The first clinical trial of the Oxford vaccine is "progressing well", he said, noting that all Phase 1 participants recently received their vaccine dose.
CSL told News Corp its vaccine subsidiary Seqiris was already working with the University of Queensland and could produce its world leading COVID-19 vaccine candidate.
The investment came through the long-running partnership that Sanofi holds with the Biomedical Advance Research and Development Authority (BARDA), with the two partnering initially on a SARS vaccine before then beginning work on a vaccine for COVID-19 in February - providing additional funds at the same time.
The UK recently made a development towards this initiative when it announced that it would construct a £38 million facility to mass produce a COVID-19 vaccine which is now under trial.
"Some of that capacity exists but we want to see what we can do particularly with COVID, whether we discover the vaccine or prove that vaccine ourselves or whether we are manufacturing from other countries".
Asked if the vaccine could be ready by September, Professor Gilbert replied: "Yes and we have to go for that.' She added it was 'just about possible if everything goes perfectly".
If a vaccine is identified, production should be "globally distributed" to guard against "vaccine nationalism", she said.
Oxford's coronavirus vaccine shows promise in animal trials
In a further announcement, Sharma said a global licensing agreement had been finalised between Oxford University and AstraZeneca . Another 18.5 million pounds will go to Imperial College London as trials accelerate.
Negotiations are underway at a global level to ensure any vaccine is shared around the world and that people living in poorer countries also get access to it. "The speed at which Oxford University has designed and organized these complex trials is genuinely unprecedented".
"Our scientists are at the forefront of vaccine development", business secretary Sharma said in a statement.
It comes as Oxford University agrees a global licensing agreement with AstraZeneca for the commercialisation and manufacturing of their potential vaccine.
Researchers working towards a Covid-19 vaccine in the United Kingdom will receive £84 million in funding, business secretary Alok Sharma has announced.
If the vaccine is successful, the 30 million doses would be enough to immunize almost half of Britain's population. A total of 3,142 people tested positive for the virus in the past day, taking the count of the total cases to 243,303.
Choreography Matthew Bourne echoed such opinions: "Lots of positivity in the news this morning about "UK going back to work" but until we can rehearse and play to packed theatres when can dance and theatre realistically think of returning to work without a vaccine or something similar?"
"The centre, which is already under construction, will have capacity to produce enough vaccine doses to serve the entire United Kingdom population in as little as six months".